Principal Financial Group Inc. lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 3.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 141,083 shares of the company’s stock after selling 4,752 shares during the quarter. Principal Financial Group Inc. owned 0.11% of Henry Schein worth $9,763,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. ING Groep NV bought a new stake in Henry Schein in the 3rd quarter worth approximately $63,226,000. Holocene Advisors LP bought a new stake in shares of Henry Schein in the 3rd quarter worth approximately $58,319,000. Southpoint Capital Advisors LP lifted its holdings in shares of Henry Schein by 30.0% in the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock worth $189,540,000 after acquiring an additional 600,000 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Henry Schein in the 3rd quarter valued at $43,740,000. Finally, Bank of Montreal Can grew its holdings in shares of Henry Schein by 365.6% during the 3rd quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock valued at $52,095,000 after purchasing an additional 558,689 shares during the last quarter. 96.62% of the stock is owned by institutional investors.
Henry Schein Stock Performance
Shares of Henry Schein stock opened at $72.17 on Friday. Henry Schein, Inc. has a 12 month low of $63.67 and a 12 month high of $82.49. The firm has a market capitalization of $9.00 billion, a P/E ratio of 29.70, a P/E/G ratio of 2.13 and a beta of 0.91. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The business has a fifty day simple moving average of $74.35 and a two-hundred day simple moving average of $72.42.
Analyst Ratings Changes
Several analysts have weighed in on HSIC shares. Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and boosted their price target for the stock from $69.00 to $84.00 in a research note on Monday, January 6th. UBS Group lowered their price objective on Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a research report on Wednesday. Mizuho initiated coverage on shares of Henry Schein in a report on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price target on the stock. Jefferies Financial Group upped their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Finally, StockNews.com raised Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $81.10.
Check Out Our Latest Report on Henry Schein
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Stories
- Five stocks we like better than Henry Schein
- Most active stocks: Dollar volume vs share volume
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- Why is the Ex-Dividend Date Significant to Investors?
- 5 Best Gold ETFs for March to Curb Recession Fears
- The How and Why of Investing in Gold Stocks
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.